Premium
Lessons from early clinical experience with the Afirma gene expression classifier
Author(s) -
Krane Jeffrey F.
Publication year - 2014
Publication title -
cancer cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.29
H-Index - 57
eISSN - 1934-6638
pISSN - 1934-662X
DOI - 10.1002/cncy.21472
Subject(s) - medicine , classifier (uml) , pathology , clinical decision making , bioinformatics , intensive care medicine , artificial intelligence , biology , computer science
Early clinical experience with the Afirma gene expression classifier indicates potential limitations of the test in everyday practice. The Afirma test may have diminished utility for Hurthle cell lesions. Additional challenges include high test cost relative to repeat fine needle aspiration and the dependence of test performance on highly variable diagnostic thresholds in cytology and surgical pathology specimens.